News | May 13, 2013

New Era in Pediatric Interventional Cardiology Training Needed

Frank Ing spotlights need for new training initiatives to meet challenges, opportunities of the future during SCAI

May 13, 2013 — The impact of pediatric interventional cardiology has never been stronger, nor the need for organized, high-quality training greater, says Frank F. Ing, M.D., FSCAI, who delivered the annual Mullins Lecture at the Society for Cardiovascular Angiography and Interventions (SCAI) 2013 Scientific Sessions. He made the case that advances in technology and growth in the profession mean that now is the time to take training to the next level.

“We’re experiencing a golden era in pediatric interventions,” said Ing, the associate chief of cardiology and director of the cardiac catheterization laboratory at Children’s Hospital Los Angeles. “We’re crossing a threshold that establishes this as a legitimate field that will have a huge impact on pediatric cardiology. As such, we need to start thinking more about how we train the people doing these procedures, to maintain quality and to maintain a movement going forward.”

In his keynote address, Ing focused on the past, present and future of training in pediatric interventional cardiology. Afterward, he co-moderated a panel discussion on fellowship training.

The issue of training in pediatric interventional cardiology is becoming increasingly important these days. Not only have multiple pediatric interventional devices been approved by the U.S. Food and Drug Administration (FDA), but pediatric cardiologists increasingly collaborate with interventionalists specializing in adult structural heart disease and perform hybrid procedures with congenital heart surgeons.

The Mullins Lecture, and the panel discussion afterward, explored the need for guidelines on fellowship training in pediatric interventional cardiology. Scheduled to be published soon, the guidelines are expected to include recommendations on the scope of fellowship training and the minimum number of cases needed to develop expertise in specific pediatric interventional procedures.

“To move forward, you have to maintain a legacy of teaching, of impacting the next generation and their careers and of adding to the science of the field,” he said. “We’ve done it all along, but in a random fashion. Now we have enough critical mass to think hard about organizing official guidelines and some common techniques to training, perhaps using SCAI as a sponsoring umbrella organization.”

 For more information: www.scai.org

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init